Husain N, Chiocca E A, Rainov N, Louis D N, Zervas N T
Molecular Neuro-oncology Laboratories, Massachusetts General Hospital, Charlestown 02129, USA.
Acta Neuropathol. 1998 Mar;95(3):287-90. doi: 10.1007/s004010050799.
Fas ligand (FasL) is involved in tumor evasion from the immune system. We analyzed 22 human gliomas for expression of FasL and its receptor, Fas. Positive FasL and Fas immunoreactivity was detected in 13 out of 22 tumors by Western blotting and in 15 out of 22 tumors by immunohistochemistry. Immunohistochemistry also showed that Fas and FasL expression was confined to tumor cells. Co-expression of these molecules was confirmed by Western blotting and immunohistochemistry in 4 of 7 glioma cell lines. Co-expression of FasL and Fas within tumor cells suggests that their contribution in vivo to the process of immune system evasion and tumor cell apoptosis is complex and probably involves additional factors.
Fas配体（FasL）参与肿瘤对免疫系统的逃逸。我们分析了22例人类胶质瘤中FasL及其受体Fas的表达情况。通过蛋白质印迹法在22个肿瘤中的13个检测到FasL和Fas的阳性免疫反应性，通过免疫组织化学法在22个肿瘤中的15个检测到阳性反应。免疫组织化学还显示Fas和FasL的表达局限于肿瘤细胞。通过蛋白质印迹法和免疫组织化学法在7个胶质瘤细胞系中的4个证实了这些分子的共表达。肿瘤细胞内FasL和Fas的共表达表明它们在体内对免疫系统逃逸和肿瘤细胞凋亡过程的作用是复杂的，可能涉及其他因素。
